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miR-205-5p-mediated downregulation of ErbB/HER
receptors in breast cancer stem cells results in targeted
therapy resistance
A De Cola1, S Volpe2, MC Budani1, M Ferracin3, R Lattanzio1, A Turdo2, D D’Agostino1, E Capone1, G Stassi2, M Todaro2, C Di Ilio1,
G Sala1,4, M Piantelli1, M Negrini3, A Veronese1 and V De Laurenzi*,1
The ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its
receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been
approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-
positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells
have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs),
may not respond to these therapeutic agents. Accumulating evidences indicate that miR-205-5p is significantly downregulated in
breast tumors compared with normal breast tissue and acts as a tumor suppressor directly targeting oncogenes such as Zeb1 and
ErbB3. In this study, we report that miR-205-5p is highly expressed in BCSCs and represses directly ERBB2 and indirectly EGFR
leading to resistance to targeted therapy. Furthermore, we show that miR-205-5p directly regulates the expression of p63 which is
in turn involved in the EGFR expression suggesting a miR-205/p63/EGFR regulation.
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Breast cancer is the most frequent type of cancer in women
and despite the great improvement in diagnosis and treatment,
relevant number of patients eventually relapses (SEER
Cancer Statistics Review, 1975–2007, National Cancer
Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/,
based on November 2009 SEER data submission, posted to
the SEER web site, 2010). Recent studies have provided
strong support for the cancer stem cell (CSC) hypothesis
which holds that breast cancers are driven by a subpopulation
of cells within the tumor which display stem cell properties.1
These properties include self-renewal, which generates other
CSCs and differentiation, which generates populations of cells
forming the bulk of the tumor. There is increasing evidence that
CSCs are relatively quiescent cells, resistant to chemotherapy
and radiation therapy and can therefore contribute to
treatment resistance and relapse. It is therefore possible that
relapses observed in ErbB2-positive breast cancer patients
receiving adjuvant Trastuzumab (humanized antibody anti-
Her2-Herceptin) or Lapatinib (small tyrosine kinases inhibitor
molecule),2,3 is due to the presence of CSCs that escape
these therapeutic agents. Various mechanisms have been
reported to cause resistance to targeted therapy, such as
reduced ErbB2 expression, increased pro-survival signaling
through alternative tyrosine kinases receptors or altered
intracellular signaling leading to cellular over-proliferation.4,5
Virtually all human genes are targeted by miRNAs,6 a class
of non-coding endogenous small RNAs, which modulate the
expression of their target genes through base pairing with the
30 untranslated sequence (30-UTR) of their target mRNAs.7,8
MiRNA deregulation is widely described in cancer and has an
important role in tumorigenesis.9,10
MiR-205-5p is a highly conserved miRNA, expressed
in stratified squamous epithelial-derived tissues11 and in
mammary gland progenitor.12 It has been shown that
miR-205-5p is downregulated in breast cancer and can
specifically suppress ErbB3 expression.13 Moreover, miR-205-5p
has been reported to mediate the epithelial to mesenchymal
transition by targeting ZEB1 and ZEB2,14,15 and it has a role in
targeting several regulators of proliferation16,17 suggesting its
involvement in cellular differentiation, migration and prolifera-
tion. In addition, it has been reported that miR-205-5p is
regulated by p63, a p53 family member resulting in epithelial to
mesenchymal transition inhibition,18 whereas the loss of the
p63/miR-205 axis enhances cell migration and metastasis in
prostate cancer cells.19
The TP63 gene contains two promoters that produce two
proteins: the full-length TAp63 that contains functional
N-terminal transcriptional transactivation (TA) domains and
the ΔNp63 protein, which lacks TA domains.20 p63 has central
roles in epithelial development and despite the two isoforms
share some common features,20 TAp63 mainly acts as tumor
suppressor and ΔNp63 as an oncogene.21,22
Here, we show that miR-205-5p is upregulated in
patient-derived breast CSCs (BCSCs), compared with more
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differentiated tumor cells. More importantly, we show that
miR-205-5p controls CSC phenotype targeting ErbB2, p63
and EGFR, contributing to targeted therapy resistance.
Results
BCSCs show low levels of ERBB2 and EGFR. We
characterized three patient-derived BCSC lines (BCSC #1,
BCSC #2, BCSC #3) from three ErbB2-positive primary
tumors. Immunohistochemistry analysis (Figure 1a) of the
primary tumor confirms ErbB2 positivity in all three tumors,
whereas CSCs derived from the tumors stain negative.
Interestingly, when cells are grown as differentiating sphere-
derived adherent cells (SDACs) for 14 days, they begin to
show a faint positive staining. Western blot analysis confirms
that spheroids retain very low expression levels of both ErbB2
and EGFR receptors that significantly increase when
cells were grown as SDACs (Figure 1b). FACS analysis
(Supplementary Figure S1) further confirms that indeed all
three cell lines express variable (but generally low) levels of
ErbB2 that again increase when cells are grown as SDACS.
Interestingly, there is little correspondence between mRNA
(Figure 1c) and protein levels for ErbB2 and almost none for
EGFR, suggesting that expression changes in BCSCs and
SDACs are at least in part mediated by non-transcriptional
mechanisms. These data suggest that although CSCs show
low expression levels of ErbB2 and EGFR, these receptors
increase in tumor cells when they acquire a more differ-
entiated phenotype.
BCSCs are resistant to Lapatinib. We then tested the
sensitivity of cell lines grown as mammospheres to Lapatinib,
an ATP-competitive reversible small-molecule inhibitor of the
ErbB2 and EGFR tyrosine kinases currently used in clinics as
therapy for Her2-overexpressing metastatic breast cancers
resistant to Trastuzumab-based regimens.23 As shown in
Figure 1d, cells are resistant to treatment consistently with
low expression levels of the receptors.
We then investigated whether cells regain sensitivity to this
treatment when they are grown as SDAC and increase
receptors expression. Indeed although BCSCs are completely
resistant to treatment with Lapatinib (0.5 μM), the same cells
grown as SDACs appear significantly more sensitive
(Figure 1d). These results suggest that failure of therapies to
target BCSCs could be at least in part due to reduced
expression of the receptors.
There have been a number of studies describing a role of
miRNA in the regulation of protein expression in normal and
tumor breast stem cells. Moreover, a number of miRNAs have
been shown to be involved during carcinogenesis,24,25
and emerging evidence suggests that miRNAs also have
essential roles in stem cell self-renewal and differentiation
by negatively regulating the expression of key genes.25
Therefore, we performed a miRNA expression profile to
identify miRNAs differentially expressed in BCSCs (BCSC #1)
and SDACs collected at the indicated time point (7 days), and
we identified 58 human miRNAs significantly differentially
regulated (adjusted Po0.05). Among these, several have
been previously shown to be involved in breast malignancy.
Supplementary Figure S2 shows miRNAs that presented the
highest differences between BCSCs and SDACs. We focused
our attention on miR-205-5p because it has been previously
reported12,26–29 to have a role in both normal mammary
development and in breast cancer. MiR-205 has also been
shown to be highly expressed in stem cell-enriched popula-
tions from normal mouse mammary gland, and thus may have
a function also in maintaining the BCSC phenotype. We
confirmed a higher expression of miR-205-5p in BCSCs as
compared with SDACs in all three cell lines (Figure 2a). This
inversely correlates with expression of ErbB2 and EGFR, thus
suggesting that miR-205 is potentially a regulator of these
receptors.
miR-205-5p regulates ERBB2 and EGFR expression. To
investigate whether miR-205-5p is indeed capable of
regulating ErbB2 and EGFR expression, we silenced it in
BCSC by cloning the miR-205-5p mature sequence in a
pSIH-H1 shRNA expression lentivector. As shown in
Figure 2b, miR-205-5p knockdown results in a significant
EGFR and ErbB2 upregulation at protein levels as well as
at mRNA levels (Figure 2c). ZEB-1, a well-established
miR-205-5p target, was used as a control to confirm
functional miR-205-5p silencing.
In addition, overexpression ofmiR-205-5p in BCSC #1 cells
by infection with pCMV-RFP-2A-puro lentivector results in
strongly reduced protein levels (Figure 2d) and in reduced
mRNA levels (Figure 2e) of both ErbB2 and EGFR. Similar
results were obtained using the same constructs in the other
two BCSC lines (data not shown), suggesting a possible direct
regulation of these two genes by miR-205-5p.
Because the main algorithms for miRNA target prediction
fail to find the EGFR and ErbB2 as target of miR-205, we
performed an in silico analysis using the RNAhybrid algoritm
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.
html) to identify putative target sites for miR-205-5p in the
3′-UTR of human ErbB2 (NM_004448) (Figure 2f) and of
human EGFR (Figure 2g) (NM_005228). We found few
putative binding region, therefore we cloned both ErbB2 and
EGFR 30-UTR containing the predicted miR-205-5p binding
site into the pGL3 control vector downstream of the luciferase
open reading frame. Co-transfection of mimic premiR-205 and
the WT ErbB2 3′-UTR construct in SKBR3 cells results in a
significant inhibition of the luciferase activity compared
with cells in which the WT ErbB2 3′-UTR construct was
co-transfected with a control vector (Figure 2f). Mutation of
miR-205-5p binding site within the ErbB2 3′-UTR (ERBB2-
30-UTRMut) abolishes the ability ofmiR-205-5p to regulate the
luciferase expression resulting in the increase of luciferase
activity (Figure 2f). In contrast, different results were obtained
co-transfecting miR-205-5p and the WT EGFR 30-UTR
construct in SKBR3 cells. Indeed, as shown in Figure 2g,
miR-205-5p was not able to decrease luciferase activity, even
at longer time points (24, 48 and 72 h after transfection).
These data suggest that miR-205-5p might modulate EGFR
expression indirectly, by targeting others key factors involved
in EGFR regulation.
miR-205-5p controls p63 expression. To further investigate
the indirect regulation of EGFR expression by miR-205-5p,
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Figure 1 ERBB2 and EGFR expression pattern in BCSCs and during differentiation. (a) Immunohistochemistry of three different paraffin-embedded primary tumor tissues
(left), CSCs lines derived from tumors (centre) and SDACs (right) stained with anti-HER2 antibodies (pink-brown) (Scale bar: 20 μM). ERBB2 is expressed in primary tumors but
not in CSCs lines and starts to be re-expressed under differentiating condition (SDAC). (b) Western blot analysis of BCSC lines (BCSC#1, BCSC#2 and BCSC#3) and stem cells
under differentiating condition (SDAC) for 3.5 and 7 days using antibodies against ERBB2, EGFR and Actin as a loading control. The corresponding molecular weights are
indicated on the left (KDa). ERBB2 and EGFR expression increases during differentiating condition. (c) qRT-PCR of ERBB2 and EGFR levels of BCSC lines (BCSC#1, BCSC#2
and BCSC#3) and SDAC of the same lines differentiated for 3.5 and 7 days. Data represent mean± S.D. of three different experiments analyzed in triplicate. Statistical
significance was analyzed using Student’s T test (*Po0.05). (d) BCSCs are resistant to Lapatinib treatment. Cell proliferation assay of BCSCs and SDAC untreated (ctr) or
treated with 0.5 μM of Lapatinib at the indicated time points (days). SDAC were differentiated for 3.5 days and then plated for growth curve analysis. BCSCs express low receptors
levels and are more resistant to treatment than SDAC. Data represent mean±S.D. of three different experiments and P values are shown in the graphs
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we studied the role of p63 in this pathway, because it has
been reported to promote the transcription of EGFR.30
Interestingly, it has also been shown that p63 controls
miR-205-5p expression.18,19
To evaluate the potential role of p63 in miR-205-5p -ERBB
family axis, we first checked the expression levels of p63 in our
model. As shown in Figure 3, all three lines tested express
detectable mRNA (Figure 3a) and protein (Figure 3b) levels of
p63. In addition, we tested whether p63 was also able to drive
the expression of EGFR in BCSCs as previously reported. As
shown in Figure 3c, silencing of p63 in BCSC #1 cells results in
reduced expression of EGFR, whereas upregulation of the ΔN
but not the TA isoform results in increased EGFR levels
(Figure 3d). Interestingly, p63 levels increase in more
differentiated cancer cells as compared with cells grown as
spheroids in parallel with the reduction of miR-205-5p
expression (Figure 3e). We therefore investigated whether
miR-205-5p is capable of regulating p63 expression. As
shown in Figure 4a, miR-205-5p knockdown results in a
significant p63 upregulation both at the mRNA and protein
levels. Consistently, miR-205-5p overexpression results in
reduced p63 levels (Figure 4b). Bio-informatic analysis of p63
30-UTR identified a putative miR-205-5p seed region
(Figure 4c, left). We therefore cloned the p63 3’-UTR contain-
ing the miR-205-5p binding site into the pGL3 control vector
downstream the luciferase gene. Co-transfection of
premiR-205 and the WT p63 3′-UTR construct in SKBR3
cells resulted in significant inhibition of luciferase activity
compared with the cells in which theWT p63 3′-UTR construct
was co-transfected with a control vector (Figure 4c, right).
These datawere confirmed bymutation ofmiR-205-5p binding
site within the p63 3′-UTR (p63-3’-UTRMut) that abolishes the
ability of miR-205-5p to regulate the luciferase expression
leading to an increase of luciferase activity. We therefore
believe that miR-205-5p regulates expression of EGFR
through regulation of ΔNp63. Interestingly, we confirm that
as reported in literature, p63 regulatesmiR-205-5p expression
thus creating a regulatory feedback loop. In fact, p63 silencing
Figure 3 p63 expression pattern in BCSCs and during differentiation. (a) p63 expression pattern in BCSCs. TAp63 (left) and ΔNp63 (right) expression levels in BCSC#1,
BCSC#2 and BCSC#3 were assessed by qRT-PCR. All three stem cell lines tested show p63 detectable levels. (b) Western blot analysis of p63 protein levels in BCSC#1,
BCSC#2 and BCSC#3 normalized with Actin levels. Numbers on the left indicate molecular weight (KDa) and symbol on the right indicate * Tap63 and ** ΔNp63, respectively.
(c) EGFR protein levels in BCSC#1 infected with p63 silencing (shp63) lentivector. p63 silencing leads to EGFR downregulation. (d) ΔNp63 and not Tap63 regulates EGFR
expression. Western blot of EGFR protein levels in BCSC#1 infected with TAp63 or ΔNp63 overexpression lentivector or a control vector (Empty). (e) p63 expression pattern in
BCSC#1, BCSC#2 and BCSC#3 and SDAC collected at 3.5 and 7 differentiation days. Western blot of p63 levels shows an increase of both TAp63 and ΔNp63 isoforms during
differentiating condition (middle: long exposure to better evaluate p63 expression in all three BCSC lines)
Figure 2 miR-205-5p regulates ERBB receptors expression in BCSCs. (a) qRT-PCR quantification of miR-205-5p expression in BCSC#1, BCSC#2 and BCSC#3 and SDAC
differentiated for 3.5 and 7 days. miR-205-5p is downregulated during differentiation in all three stem cell lines tested. Data represent mean± S.D. of three different experiments
analyzed in triplicate. (b and c) miR-205-5p regulates ERBB2 and EGFR expression. qRT-PCR and western blotting analysis of EGFR and ERBB2 expression levels in BCSC#1
infected withmiR-205-5p silencing lentivector (shmiR-205-5p). miR-205 knockdown results in EGFR and ErbB2 upregulation both at the mRNA and protein levels. ZEB-1, a well-
established miR-205 target, was used as a control to further confirm functional miR-205 silencing. (d and e) miR-205-5p overexpression results in ERBB receptors
downregulation. qRT-PCR and western blot analysis of EGFR, ERBB2 and Zeb-1 expression levels in BCSC#1 infected with PremiR-205 lentivector. All qRT-PCR data represent
mean±S.D. of three different experiments analyzed in triplicate. (f) miR-205-5p directly targets ERBB2 at 3’-UTR. Schematic model of the predicted ERBB2 3’-UTR binding site
for miR-205-5p and alignment of the seed region with both wild-type and mutated ERBB2 3’-UTR (left). On the right, relative luciferase activity is shown. SKBR-3 cells were co-
transfected for 24 h with pGL3-ERBB2 3’-UTR luciferase construct (WTor Mut 3’-UTR), premiR 205 construct or a control vector (CTR). The results represent mean±S.D. of
three different experiments analyzed in triplicate. (g) EGFR is not a direct target of miR-205-5p. Representation of the interaction between miR-205-5p and the putative binding
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results in reduced miR-205-5p levels (Figure 4d), whereas
upregulation of the ΔN but not the TA isoform results in
significant increase of miR-205-5p levels (Figure 4e).
We therefore sought out to re-sensitize BCSCs to Lapatinib
treatment downregulating mir-205-5p, that we showed is
responsible for reduced expression of EGFR and ErbB2 in
these cells. As shown in Figure 4f, silencing miR-205-5p in
BCSCs and treating them with Lapatinib strongly reduces cell
proliferation, sensitizing cells to anti-Her2/EGFR treatments.
These findings indicate that miR-205-5p is able to regulate
ErbB receptors expression thus leading to targeted therapy
resistance of BCSCs.
Discussion
Growing evidence suggest that a subset of cells within the
tumor, refered as CSCs are capable of escaping anti-cancer
treatment driving tumor progression, metastasis and relapse.1
Many studies have therefore focused on the identification of
pathways that are essential in determining the CSC pheno-
type. It iswell known that miRNAs contribute to carcinogenesis
and tumor development acting as oncogenes or as tumor
suppressors depending on specific targets and tumor micro-
environment. Altered miR-205-5p expression has been
involved in several types of solid tumors and, to date, its
target include tumor suppressors like PTEN12 and SHIP2,31
oncogenes such as HER3,32 PKCε,17 pro-metastatic factors
Zeb1 and Zeb-2,14 and the angiogenic gene VEGFA.32
Moreover, miR-205-5p has been shown to be essential for
mouse development,33,11 particularly for the expansion of
progenitor and stem cell populations in epidermis, hair follicles
and more importantly in mammary gland during neonatal
development;33,12 therefore, we hypothesize its mis-regulation
could be translated in maintaining the CSC phenotype. In
breast cancer, miR-205-5p was found to be either up- or
downregulated compared with normal tissue, but its
Figure 4 miR-205-5p regulates p63 expression in BCSCs. (a) miR-205-5p regulates p63 levels. qRT-PCR (left) and western blotting analysis (right) of p63 expression levels
in BCSC#1 infected withmiR-205-5p silencing lentivector (shmiR-205-5p). (b) qRT-PCR (left) and western blotting (right) of p63 expression levels in BCSC#1 infected with Premir-
205 lentivector. miR-205-5p overexpression results in p63 downregulation mainly at protein levels. (c) miR-205-5p directly targets p63-3’-UTR. On the left, putative miR-205-5p
binding site on p63 wild-type 3’-UTR and alignment of the seed sequence with both WTand mutated p63 3’-UTR. On the right, SKBR-3 cells were co-transfected for 48 h with
pGL3-p63 3’-UTR luciferase construct (WTor Mut 3’-UTR), premiR 205 construct or a control vector (CTR). Cloning p63 3’-UTR WT, and not the mutated one, into a luciferase
reporter gene leads to diminished luciferase activity in the presence of Premir-205. (d) p63 regulates miR-205-5p expression. qRT-PCR of miR-205-5p expression levels in
BCSC#1 infected with shp63 lentivector (shp63) or a control vector (plentilox). (e) qRT-PCR of miR-205-5p expression levels upon Tap63 or ΔNp63 overexpression in BCSC#1.
ΔNp63 overexpression results in miR-205-5p upregulation. (f) miR-205-5p downregulation re-sensitize BCSCs to Lapatinib treatment. Percentage of cell growth of BCSC#1,
BCSC#2 and BCSC#3 infected with shmiR-205-5p lentivector (shmiR-205-5p) or a control vector (CTR) and treated or untreated with 0.5 μM Lapatinib for 6 days
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expression in BCSCs remains still unknown. Here, we show
that miR-205-5p is highly expressed in human BCSCs
compared with more differentiated tumor cells and that it
directly targets ERBB receptors leading to their downregula-
tion. In fact while it was known that ERBB3 is a direct target of
miR-205-5p, we show that it also regulates ErbB2 and EGFR.
While ErbB2 appears to be a direct target of this miR, EGFR
regulation is mediated through the regulation of p63 that has
already been shown to be able of regulating transcription of
EGFR.30 Indeed, here we show for the first time that p63 is a
direct target of miR-205-5p and confirm previous reports
showing that in turn ΔNp63 regulates miR-205-5p
expression.19,18 These data show that, therefore, there is a
feedback loop finely regulating expression ofmiR-205-5p and
p63 that have a role in determining some of the phenotypic
features of BCSCs including surface expression of ERBB
receptors.
Intriguingly, we show that low expression of ERBB receptor
family members in BCSCs contributes to resistance of these
cells to agents such as Lapatinib used in breast cancer
therapy. Survival of these cells could then lead to tumor
progression and suggests that miR-205-5p could be an
important target to improve outcome of patients with Her2-
overexpressing breast cancer.
In conclusion, we want to point out that we identified for the
first time two new direct targets ofmiR-205-5p and shown that
this miRNA has an important role in determining BCSCs
phenotype and contributes to their resistance to targeted
therapy.
Materials and Methods
BCSC isolation and culture. BCSCs were isolated from human breast
cancer tissues obtained from patients as previously described34 and were cultured
in a selective medium34 supplemented with 10 ng/ml βFGF (Peprotech, London,
UK), 20 ng/ml EGF (Peprotech) to a final concentration 5 × 104/ml in ultra low
attachment flask (Corning, New York, NY, USA) at 37 °C in a 5% (v/v) CO2
humidified chamber. BCSCs were induced to differentiate in order to obtain SDACs
by culturing them in adherent condition in D-MEM with high glucose (Euroclone,
Milan, Italy) supplemented with 10% (v/v) fetal bovine serum (Euroclone). The tumor
s were histopathologically classified as follows: BCSC#1 is an invasive ductal
carcinoma, grading G2, ER 90%, PR 60%, HER2/neu 3+ and ki67410%; BCSC#2
is an invasive ductal carcinoma, grading G2, ER 90%, PR 60%, HER2/neu 3+ and
ki67 25%, BCSC#3 is an invasive ductal carcinoma, grading G2, ER 80%, PR 80%,
HER2/neu 3+ and ki67 410%. HER2 status has been assigned according to the
FDA guidelines.
Constructs. To generate miR-205-5p expression lentiviral vector, a 326 bp
fragment carrying pre-miR-205 was amplified from H1299 genomic DNA by the
Platinum Taq polymerase high fidelity (Life Technologies, Waltham, MA, USA) using
PCR primers: miR-205 F 5′-cggctagccgaggtccttgacatct-3′ and miR-205 R 5′-ccctcg
agggcctaagtcagagtta-3′.
The amplified fragment was cloned into pLenti-CMV-RFP-2A-Puro (Applied
Biologicals Marerials Inc., Richmond, BC, Canada) lentiviral vector at Nhe-XhoI sites.
To generate shRNA miR-205 lenti-vector, we cloned miR-205-5p into pSIH-H1-
copGFP Vector (System Biosciences, Mountain View, CA, USA), at EcoRI-BamHI
sites, using PCR oligonucleotides:
shmiR-205 1 5′-gatcctccttcattccaccggagtctgcttcctgtcagacagactccggtggaatgaagga
tttttg-3′ shmiR-205 2 5′-aattcaaaaatccttcattccaccggagtctgtctgacaggaagcagactccg
gtggaatgaaggag-3′.
To generate a luciferase reporter carrying the ErbB2-3’-UTR with a putative
miR-205-5p binding site, we amplified a 512 bp fragment by PCR from the first
nucleotide after the stop codon to the last nucleotide before the polyadenylation
signal from human genomic DNA using the following primers: ERBB2-UTR SpeF
5′-gactagtcaccagaaggccaagtccg-3′ and ERBB2-UTR SpeR 5′-ggactagtcctcatc
tttaaaaaaacaaaac-3′. The fragment, after SpeI restriction, was ligated to a compatible
XbaI linearized pGL3 Control vector (Promega, Madison, WI, USA). The miR-205-5p
predicted target site (5 bp, GAAGG) was deleted by PCR using the following primers:
Her2MutFw 5′- gccctgatgtgtcctcagggagcaggcc-3′ and Her2MutRev 5′-tgatgccagc
agaagtcaggcctgctcc-3′ with QuikChange Lightning Site-Directed Mutagenesis kit
(Agilent Technologies, Santa Clara, CA, USA).
The same procedure was used to clone 2770 bp p63 3’-UTR fragment in a pGL3
Control vector using the following primers: p63UTR-SpeIF 5’-ggccactagtgcctcac-
catgtgagctcttc-3’; p63UTR-SpeIR 5′-ggccactagtgcatgtcctggcaaacaaaaagag-3′ as
previously described.35 Mutation (5 bp, GGAAU) was introduced into the miRNA
binding site with QuikChange Lightning Site-Directed Mutagenesis kit (Agilent
Technologies) using the following primers: Fwp63Mut gtttttggttggaggaaaattctt
aaaaggcccatagcagc
Revp63Mut gctgctatgggccttttaagaattttcctccaaccaaaaac.
EGFR 3’-UTR WT luciferase reporter vector was kindly provided by CM Croce
(Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Columbus, OH, USA).
To generate TAp63α-Tween and ΔNp63α-Tween expression lentiviral vectors, we
subcloned inserts from TAp63α− pcDNA and ΔNp63α− pcDNA constructs, kindly
provided by Prof. G Melino,36 into XbaI-XhoI unique sites of Tween lentiviral vector37
under the control of hCMV promoter. This vector constitutively expresses GFP under
the control of hPGK promoter.
For shp63 construct, to downregulate p63 expression, the pLL3.7-p63-7.2 was
generated by insertion in pLL3.7 vector (Addgene plasmid 11795, Addgene,
Cambridge, MA, USA) of oligos targeting the following sequence: GAGTGGAATGAC
TTCAACTTT.38
The cloning was performed according to the pLL3.7 protocol from the Tyler Jacks
laboratory at MIT (https://www.addgene.org/static/data/94/67/16242780-af64-11e0-
90fe-003048dd6500.pdf).
A CMV-EGFP reporter cassette is included in the vector to monitor expression.
All PCR products were verified by DNA sequencing.
Infections. Lentiviruses were produced by transient cotransfection of a three-
plasmid expression system in the packaging 293T cells, using the calcium
phosphate transfection kit (Invitrogen, Life Technologies). Cells were incubated for
7 h with the transfection reagents and viral supernatant was collected 48 h after
transfection and filtered through 0.45 μm pore vacuum sterile filtration system
(Millipore, Life Science, Darmstadt, Germany). Then, BCSCs were plated in a six-
well ultra-low attachment plate (Corning) with viral supernatant and 4 μg/ml of
polybrene. Plates were centrifuged for 45 min at 1800 r.p.m. and incubated at 37 °C
for 75 min in a 5% CO2 humified chamber. Cells were then washed twice and
replated in fresh medium.39 Infection efficiency was assessed by flow cytometry
(FACSCanto II Instrument, BD Biosciences, San Jose, CA, USA) 48 h post-infection
evaluating the percentage of GFP-positive or RFP-positive cells measured. Data
were analyzed with CELLQuest software (BD Biosciences).
Quantitative reverse transcription-PCR. For miRNA detection, RNA
was extracted from BCSCs by using miRVana miRNA Isolation kit (Ambion by Life
Technologies). A total of 50 ng of RNA was used for reverse transcription using
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystem by Life
Technologies) with the following stem loop specific primers: miR-205-5p RT: 5′-gttgg
ctctggtgcagggtccgaggtattcgcaccagagccaaccagact-3′ and U44-RT: 5′-gttggctctggt
gcagggtccgaggtattcgcaccagagccaacagtcagtt-3′.
Real-time PCR was performed by using FastStart Universal Probe Master (Rox)
(Roche, Basel, Switzerland) and Universal Probe Library, Probe #21 (Roche) using
the following primers: miR-205-5p Fw 5′-gcggcggtgtagtgtttccta-3′ and universal
Reverse primer: 5′-gtgcagggtccgaggt-3′. miR-205-5p expression was calculated
relative to U44 rRNA with the following primer: 5′-gcggcggcctggatgatgatag-3′ with an
amplification protocol as follows: one cycle of 95 °C for 10 min and 40 cycles of 95 °C
for 15 s and 60 °C for 1 min on an Applied Biosystem 7900HT Sequence Detection
System (Applied Biosystems, Waltham, MA, USA). Relative quantification of miRNA
expression was calculated according to the comparative method of 2-ΔΔCT.
For detection of other genes, a total of 500 ng of RNA was used for reverse
transcription using TaqMan Reverse Transcription Reagents (Applied Bioisystem, Life
Technologies) and Real-time PCR was performed by using the Platinum SYBRGreen
qPCR SuperMix UDG with Rox (Invitrogen, Life Technologies), with an amplification
program as follows: one cycle of 95 °C for 3 min and 40 cycles of 95 °C for 20 s and
60 °C for 1 min. The reaction was followed by a melting curve protocol according to
the specification of the ABI 7900HT instrument (Applied Biosystems). Primers used
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were as follows: Tap63 (NM_003722.4) F: 5′-ttgagattagcatggactgtatcc-3′and R:
5′-gttctgaatctgctggtccat-3′; ΔNp63 (NM_001114980.1) F: 5′-ggttggcaaaatcctggag-3′
and R: 5′-ggttcgtgtactgtggctca-3′. For ErbB2 (NM_004448.2) F: 5′-gggaaacct
ggaactcacct-3′ and R: 5′-ccctgcacctcctggata-3′; for EGFR (NM_005228.3) F: 5′-ttcc
tcccagtgcctgaa-3′ and R: 5′-gggttcagaggctgattgtg-3′; for ZEB1 F: 5′-gcacaaccaag
tgcagaaga-3′ and R: 5′-gcctggttcaggagaagatg-3′.
All genes expression were normalized using human β-actin as housekeeping
gene, and primers used were ActF 5′-cagctcaccatggatgatgatatc-3′ and ActR
5′-aagccggccttgcacat -3′. Relative quantification of gene expression was calculated
according to the comparative method of 2-ΔΔCT.
Microarray. Total RNA was extracted from BCSC #1 BCSCs and from BCSC #1
differentiated cells at 7 days, according to Trizol protocol (Ambion by Life
Technologies). Total RNA was used for miRNA microarray analysis (G4470B,
Agilent Technologies). This chip allows the simultaneous analysis of 723 human
miRNAs (miRBase release 10.1). RNA labeling and hybridization were performed in
accordance to the manufacturer’s indications. Agilent scanner and the Feature
Extraction 10.5 software (Agilent Technologies) were used to obtain the microarray
raw data. Microarray results were analyzed using the GeneSpring GX 12 software
(Agilent Technologies). Data transformation was applied to set all the negative raw
values at 1.0, followed by Quantile normalization and log2 transformation.
Differentially expressed miRNAs were identified by using a moderated t-test and
Benjamini-Hochberg correction (adjusted Po0.05). Differentially expressed genes
were used in Cluster Analysis, using the Pearson correlation as a measure of
similarity.
Western blotting. Proteins were extracted with a lysis buffer (TRIS-HCl 50
mM pH 8, NaCl 150 mM, Triton X-100 1%, NaF 100 mM, EDTA 1 mM, MgCl2 1 mM,
Glycerol 10%) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO,
USA) and a phosphatase inhibitor cocktail (Roche) as previously described.40 Equal
amounts of total protein were subjected to SDS-PAGE and then electrotransferred to
nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk
in PBS with 0,1% Tween 20 and incubated overnight using the following antibodies:
anti β-Actin A5441 (Sigma-Aldrich), anti-EGF Receptor (D38B1) XP Rabbit mAb
(Cell Signaling, Danvers, MA, USA), anti-ErbB2 (D8F12) XP Rabbit mAb (Cell
Signaling) anti-ZEB1 (Millipore, Life Science), anti-p63 Y4A3 (Sigma-Aldrich) or
anti-p63 alpha (D2K8X) XP Rabbit mAb (Cell Signaling). After wash, membranes
were hybridized with horseradish peroxidase-conjugated secondary antibodies
(rabbit and mouse, Bio-Rad, Hercules, CA, USA). Detection was performed with
Plus-ECL chemiluminescence kit (PerkinElmer, Inc., Waltham, MA, USA) or with
SuperSignal West Dura extended duration substrate kit (Thermo Scientific,
Waltham, MA, USA).
Immunohistochemistry. BCSCs and SDACs derived from BCSC#1,
BCSC#2 and BCSC#3 lines, were spotted on microscope slides with cytospin at
900 r.p.m. for 3 min and then were fixed in formalin 10% neutral buffered for 15 min.
BCSC, SDAC and paraffin-embedded primary tumor tissues were stained using
rabbit polyclonal (HercepTest, Dako, Glostrup, Denmark) antibodies following the
manufacturer’s instructions. Antigen-antibody reaction was visualized using an anti-
rabbit #K4003 polymer-based detection system (EnVision Kit, Dako), and using
diaminobenzidine as the chromogen. In control sections, the specific primary
antibody was replaced with rabbit non immune serum. Primary tumors BCSC #1,
BCSC#2 and BCSC#3 were scored according to HercepTest (HT) (Dako) and
classified as HT 3+.41
Luciferase assay. Human breast carcinoma cell line (SKB-R3) was grown in
McCoy's 5A Medium (Euroclone, Milan, Italy) supplemented with 10% (v/v) fetal
bovine serum (Euroclone). A total of 8 × 104 SKB-R3 cells were seeded in 12-well
dishes 24 h before transfection. Three hundred and twenty-five nanograms of pGL3
vectors, 650 ng of pLenti-CMV-RFP-2 A-Puro vectors and 10 ng of Renilla luciferase
vector were co-transfected using Lipofectamine 2000 (Invitrogen by Life
Technologies). Luciferase activities of cellular extracts were measured 24 and
48 h after transfection for ErbB2 and p63 3’-UTR, respectively, and for 24, 48 and
72 h after transfection for EGFR 3’-UTR, by using a Dual-Glo-Luciferase Reporter
Assay System (Promega, Fitchburg, WI, USA) with a Lumat LB 9507 luminometer.
Efficiency of transfection was normalized using Renilla luciferase activity.
FACS analysis. For flow cytometric analysis of EGFR and ErbB2 surface
markers, 20 × 104 cells per sample, for all three BCSCs and SDACs tested
(BCSC#1, BCSC#2 and BCSC#3), were washed in PBS, resuspended in 100 μl of
specific antibody diluted in 0.5% BSA, and incubated for 20 min at room
temperature. For EGFR and ErbB2 staining 10 μg/ml Trastuzumab (Roche) and
Cetuximab (Merck Serono, Darmstadt, Germany) were used, respectively. Then,
samples were incubated for 20 min in the dark with secondary fluorescent anti-
human-R-PE-conjugated antibody (H10104, Life Technologies, 1 : 300 in 0.5%
BSA). Cell viability solution (555815, BD Biosciences) was used for detection of
non-viable cells according to the manufacturer’s protocol. Samples were then
washed and stored at 4 °C in the dark until acquisition.
A FACSCantoII flow cytometer, running with FACSDiVa software (BD Biosciences),
was used for sample acquisition and analysis.
Cell proliferation assay. BCSCs, SDACs and BCSCs infected with
shmiR-205-5p were seeded into six-well plate at 5 × 104 cells per well. Viable
cell count was performed with Trypan Blue reagent (Sigma-Aldrich) at the indicated
time points. When indicated, cells were treated with 0.5 μM Lapatinib (Biovision,
Milpitas, CA, USA).
Bioinformatics. miR-205-5p target sites on p63 3’-UTR, ERBB2 3’-UTR and
EGFR 3’-UTR were predicted by RNA Hybrid software available at http://bibiserv.
techfak.uni-bielefeld.de/rnahybrid/submission.html
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